Early-life Factors and Cancer Development Later in Life (R03 - Clinical Trial Not Allowed) | PA 18 531

Frequently Asked Questions (FAQs)

What is the focus of the NIH funding opportunity "Early-life Factors and Cancer Development Later in Life (R03 - Clinical Trial Not Allowed)"?

This NIH funding opportunity supports small, focused research projects that examine how experiences and exposures earlier in life can influence cancer risk much later. The core idea is that understanding early-life influences on biological pathways involved in carcinogenesis could strengthen cancer prevention by identifying risk long before a typical cancer diagnosis would occur.

What kinds of early-life periods and influences does the FOA cover?

The FOA spans a broad window of early development, including maternal and paternal influences, in utero conditions, birth outcomes, infancy, puberty, adolescence, and young adulthood.

What types of research questions is NIH looking for under this announcement?

NIH is interested in projects that: (1) clarify which early-life factors are associated with later cancer development, (2) investigate how those factors may alter biological processes relevant to cancer initiation and progression, and (3) explore whether early biological changes can be captured through predictive markers that might be useful in future prevention strategies.

Is this opportunity only about finding associations, or does it emphasize mechanisms too?

It emphasizes both, with strong attention to mechanism and measurement. In addition to identifying associations between early exposures and later cancer, applicants are encouraged to investigate how early-life events may mediate or program biological systems in ways that influence carcinogenesis.

What does NIH mean by "mechanism and measurement" in this FOA?

In this context, "mechanism" refers to understanding how early-life events may change biological processes related to cancer initiation or progression. "Measurement" refers to identifying intermediate endpoints such as biomarkers or other measurable traits that could serve as earlier indicators of risk, rather than waiting decades for cancer outcomes to occur.

Why is NIH interested in identifying early indicators or predictive markers of risk?

A stated motivation is practical: if researchers can validate markers that reflect early-life exposures and signal malignancy risk or pre-malignant changes, researchers would not need to wait decades for cancer outcomes to appear to evaluate long-term impacts of early-life exposures.

What is the long-term goal of the research supported by this FOA?

The long-term goal is to build a mechanistic foundation that could support targeted interventions during pregnancy or early life, when preventive actions may have a large effect on lifetime cancer risk.

What grant mechanism is being used for this opportunity?

This opportunity uses the NIH R03 mechanism, which is a small research grant program intended for short, discrete projects such as pilot studies, feasibility studies, secondary data analyses, method development, or early hypothesis-testing work designed to generate preliminary evidence for larger future grants.

What does "Clinical Trial Not Allowed" mean for applicants?

"Clinical Trial Not Allowed" means the proposed research should not include prospective assignment of human participants to interventions in order to evaluate health-related outcomes. In other words, applicants should not propose an interventional clinical trial under this FOA.

Can applicants still propose human subjects research?

Yes. The FOA indicates that human subjects research may be appropriate as long as it is not an interventional clinical trial. Examples mentioned include observational research, use of existing cohorts or biospecimens, analyses of registries or biobanks, and development or validation of predictive markers without running an interventional trial.

What types of studies are a good fit for an R03 under this FOA?

Based on the description, good fits include short, focused early-stage studies such as pilot projects, feasibility work, secondary analyses, method development, or early hypothesis-testing projects aimed at connecting early-life exposures to later cancer risk and/or establishing measurable intermediate endpoints (for example, biomarkers).

What kinds of intermediate endpoints does the FOA encourage?

The FOA highlights intermediate endpoints such as biomarkers or other measurable traits that could serve as earlier readouts of cancer risk related to early-life exposures.

Does the FOA specify particular early-life factors to study?

The FOA describes broad categories and time windows (maternal and paternal influences, in utero conditions, birth outcomes, infancy through young adulthood) rather than listing a single required exposure. It emphasizes linking early-life factors to later cancer development and to relevant biological pathways.

What role does developmental timing play in the types of projects NIH wants?

The FOA encourages research exploring how developmental timing affects susceptibility, including how physiological changes during critical growth periods might alter later cancer risk.

Who is eligible to apply for this NIH funding opportunity?

Eligibility is broad and includes many U.S. organizations and governments as well as non-U.S. entities (foreign organizations). Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits (501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); small businesses; federally recognized Native American tribal governments; and non-federally recognized tribal organizations. Public housing authorities and Indian housing authorities are also included.

Are minority-serving institutions and community-based organizations included in eligibility?

Yes. The FOA highlights additional eligible categories including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, faith-based and community-based organizations, and regional organizations.

Are U.S. territories and foreign organizations eligible?

Yes. The FOA notes eligibility includes U.S. territories or possessions and non-U.S. entities (foreign organizations).

Is this a discretionary grant, and what is the activity category?

It is listed as a discretionary grant under NIH. The activity category is noted as education and health.

What CFDA number is associated with this opportunity?

The CFDA number listed is 93.393.

What is the award ceiling mentioned in the provided information?

The source information lists an award ceiling of $50,000.

What are the key dates provided for this opportunity?

The FOA creation date shown is December 20, 2017. The original closing date shown is January 7, 2021. These dates are useful for understanding the timeline and historical context of the announcement as presented.

What is the practical payoff NIH is signaling with this FOA?

The FOA frames a future where cancer prevention is informed by early-life biology and measurable risk markers, allowing earlier assessment and potentially earlier intervention, rather than relying only on cancer outcomes that may not appear until many years after the relevant exposures occurred.